Alps Group Inc. ALPS
- Market cap
- $66.6M
- P/E
- 0.0×
Follow ALPS
Target Price Range
Analyst price targets
Free account| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | 9.77 | 9.79 | 10.19 | 10.81 | 0.56 | 0.23 |
Analyst estimates 2027–2029 Powerpack |
Low Price
|
||
| — | — | — | — | 9.86 | 10.21 | 11.67 | 12.40 | 15.00 | 1.39 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| — | — | — | — | — | 0 | — | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | 2 | 3 | 5 |
Revenue
|
|||
| — | — | — | — | — | — | — | 24.92% | 38.60% | 32.09% |
Gross Margin
|
|||
| — | — | — | — | 0 | 1 | 2 | (1) | (3) | (2) |
EBT
|
|||
| — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | (75.03%) | (42.86%) |
EBT Margin
|
|||
| 0 | — | — | — | 0 | 0 | 1 | (1) | (3) | (2) |
Net Income
|
|||
| — | — | — | — | — | — | — | 1 | 1 | 1 |
Depreciation
|
|||
| — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 |
Revenue/Sh
|
|||
| — | — | — | — | (0.04) | 0.07 | 0.38 | (0.28) | (0.02) | (0.01) |
Earnings/Sh
|
|||
| — | — | — | — | (0.11) | (0.21) | (0.41) | (0.59) | (0.01) | (0.02) |
Cash Flow/Sh
|
|||
| — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | (0.11) | (0.21) | (0.41) | (0.59) | (0.01) | (0.02) |
Free CF/Sh
|
|||
| — | — | — | — | (1.08) | (1.18) | (2.11) | (3.10) | (0.01) | (0.02) |
Book Value/Sh
|
|||
| — | — | — | — | 3 | 3 | 3 | 3 | 160 | 162 |
Shares
|
|||
| — | — | — | — | — | — | — | 144.15 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | (17.11) | (31.47) | (3.21) |
EV/FCF
|
|||
| — | — | — | — | 0 | (1) | (1) | (2) | (2) | (3) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Capex
|
|||
| — | — | — | — | 0 | (1) | (1) | (2) | (2) | (3) |
FCF
|
|||
| — | — | — | — | 1 | 0 | (4) | (7) | (6) | (4) |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | (1) | 0 | 0 | 0 | — | — |
Net Debt
|
|||
| — | — | — | — | (3) | (4) | (7) | (11) | (1) | (3) |
Sh' Equity
|
|||
| — | — | — | — | (0.10%) | 0.19% | 1.79% | (52.89%) | (46.40%) | (28.48%) |
ROA
|
|||
| — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | (0.22%) | 0.41% | (23.33%) | 10.90% | 42.60% | 92.43% |
ROE
|
|||
Alps Group Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| GOSS Gossamer Bio, Inc. | $66.8M | 0.0× | Compare |
| HYFT MindWalk Holdings Corp. | $66.9M | 0.0× | Compare |
| KLRS Kalaris Therapeutics Inc. | $67.1M | 0.0× | Compare |
| XBIT XBiotech Inc. | $65.9M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| HYPD Hyperion DeFi, Inc. | $64.8M | 0.0× | Compare |
| APLM Apollomics Inc. | $68.4M | 0.0× | Compare |
| ELOX Senesco Technologies Inc. | $64.6M | 0.0× | Compare |
| CSBR Champions Oncology, Inc. | $68.9M | 0.0× | Compare |
Alps Group Inc. (ALPS) key facts
- Alps Group Inc. (ALPS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Alps Group Inc.’s revenue for fiscal 2026 (year ended March 2026) was $4.9 million, up 44.1% from fiscal 2025.
- As of September 25, 2026, ALPS traded at $0.40, a market capitalization of $66.6 million.
- Return on equity was 92.4% and debt-to-equity 0.00.
Alps Group Inc. (ALPS) Latest News
7 Aug
Alps Group Inc reported fiscal year 2026 financial results and issued a business update. Standard earnings releases typically produce moderate short-term effects on valuation and sentiment.
Globalink Investment Inc. (GLLI) has announced an extension of the deadline to complete a business combination until September 9, 2025. This extension allows the company additional time to finalize its strategic plans and partnerships, which are crucial for its future operations and growth. The extension of the deadline may moderately influence GLLI's strategic positioning and operational planning.
23 Jun
Alps Group Inc launches patient-derived organoid program to advance personalized cancer care in Southeast Asia. Organoid program launch marks major strategic move in personalized cancer treatment innovation for Alps Group Inc. in Southeast Asia.
9 Jun
Alps Group Inc expands MyGenome accreditation to include whole genome sequencing under MS ISO 15189:2022. Accreditation expansion for MyGenome improves service capabilities in whole genome sequencing.
17 Apr
Alps Group Inc. (ALPS) appointed a former Ernst & Young partner to its Board of Directors to strengthen governance and capital markets oversight. Board appointment of former EY partner enhances governance and capital markets expertise, moderately boosting investor confidence and strategic oversight.
23 Feb
Alps Group Inc. publishes clinical data showing safety, tolerability, and effectiveness of its autologous NK cell pipeline using an in-house developed culture protocol, supporting pipeline advancement. Positive clinical data on NK cell pipeline safety and effectiveness enables advancement, significantly impacting ALPS's development trajectory and market sentiment.
30 Jan
Alps Group Inc. has announced plans for a potential pipeline expansion beyond its CELESOME(+) product following the publication of research on nebulized human umbilical cord mesenchymal stem cell exosome therapy. This development suggests a strategic move to enhance its product offerings and explore new therapeutic avenues. The potential pipeline expansion indicates a significant strategic move that could alter the company's trajectory and investor sentiment.
8 Jan
Alps Group Inc. has appointed Cheing Lye-Ping as its new Chief Financial Officer, effective immediately. Lye-Ping brings over 20 years of financial leadership experience, having previously held senior roles in various industries. The company aims to leverage her expertise to enhance its financial strategies and drive growth. The appointment of a new CFO may moderately influence the company's financial performance and strategic direction.
Globalink Investment Inc. (GLLI) has announced an extension of the deadline to complete a business combination until February 9, 2025. This extension allows the company additional time to finalize its strategic plans and potential mergers or acquisitions. The extension of the deadline may moderately influence GLLI's strategic positioning and market sentiment as it seeks to complete a business combination.
31 Oct
Alps has successfully completed its business combination with Globalink Investment Inc. (GLLI), marking a significant milestone for both companies. This merger is expected to enhance GLLI's market position and operational capabilities, paving the way for future growth and innovation. The transaction aligns with Alps' strategic objectives and is anticipated to create value for shareholders. The business combination is a major strategic move that could significantly alter GLLI's trajectory and investor sentiment.
7 Oct
Globalink Investment Inc. (GLLI) has announced an extension of the deadline to complete a business combination until November 9, 2025. This extension allows the company additional time to finalize its strategic plans and partnerships. The extension of the deadline may influence GLLI's strategic positioning and operational planning, but its overall impact is expected to be limited.
8 Sep
Globalink Investment Inc. (GLLI) has announced an extension of the deadline to complete a business combination until October 9, 2025. This extension provides the company additional time to finalize its strategic plans and partnerships, which are crucial for its future operations and growth. The extension of the deadline may moderately influence GLLI's strategic positioning and operational planning.
10 Jun
Globalink Investment Inc. (GLLI) has announced amendments to its Charter and Trust Agreement, which are expected to enhance operational flexibility and align with strategic goals. The changes aim to improve governance and facilitate future growth initiatives. Details regarding the specific amendments and their implications for shareholders were also provided. Amendments to the Charter and Trust Agreement may moderately influence the company's governance and operational strategies.
6 Jun
Globalink Investment Inc. (GLLI) has announced an extension of the deadline to complete a business combination until July 9, 2025. This extension allows the company additional time to finalize its strategic plans and partnerships, which are crucial for its future operations and growth. The extension of the deadline may moderately influence GLLI's strategic positioning and operational planning.
Globalink Investment Inc. extended the deadline for a business combination to July 9, 2024. The extension of the deadline may moderately influence the company's future business combination plans.
8 May
Globalink Investment Inc. (GLLI) has announced an extension of the deadline to complete a business combination to June 9, 2025. This extension provides the company additional time to finalize its strategic plans and partnerships, which are crucial for its future operations and growth. The extension of the deadline may moderately influence GLLI's strategic direction and market positioning.
6 Mar
Globalink Investment Inc. (GLLI) has announced an extension of the deadline to complete a business combination until March 9, 2025. This extension allows the company additional time to finalize its strategic plans and potential mergers or acquisitions. The extension of the deadline may moderately influence GLLI's strategic positioning and market sentiment.
10 Dec
Globalink Investment Inc. extended the deadline for its initial business combination to January 9, 2025 by depositing $60,000 into its trust account. The extension of the deadline may moderately influence the company's future business prospects and market performance.
6 Dec
Globalink Investment Inc. extends deadline for initial business combination to June 9, 2025, after stockholders approve charter and trust agreement amendments. 2,285,056 public shares redeemed, leaving $3.27 million in trust account. Extension of deadline for business combination may moderately influence financial performance and competitive positioning of Globalink Investment Inc.
5 Oct
OpenAI is contemplating a shift from a nonprofit to a for-profit model, which could significantly benefit Microsoft, its major investor. This transition may allow Microsoft to renegotiate profit caps and gain more influence over OpenAI's operations. However, the change could face legal and regulatory challenges, especially concerning OpenAI's valuation and its previous commitments as a nonprofit. OpenAI's recent funding round valued it at $157 billion, contingent on its for-profit status. The company is also experiencing executive turnover and increased competition, raising concerns about its future direction and regulatory scrutiny. The potential transition of OpenAI to a for-profit structure could significantly alter market dynamics and investor sentiment, impacting Microsoft's investment strategy.
6 May
Globalink Investment Inc. extends deadline for business combination to June 9, 2024. The extension of the deadline may moderately influence the company's future business combination plans.
9 Apr
Globalink Investment Inc. extended the deadline for a business combination to May 9, 2024. The extension may moderately influence the company's future business combination plans.
11 Mar
Globalink Investment Inc. extends deadline for business combination to April 9, 2024. The extension of the deadline may moderately influence the company's future business combination prospects.
7 Feb
Globalink Investment Inc. extended the deadline for a business combination to March 9, 2024. The extension of the deadline may moderately influence the company's future business combination plans.
31 Jan
Alps Global Holding Berhad to merge with Globalink Investment Inc., forming Alps Life Science Inc. with an enterprise value of US$1.6 billion, expected to be listed on Nasdaq in Q2 2024. The merger with Alps is a significant strategic move that is expected to reshape Globalink's competitive positioning and long-term prospects.
4 Dec
Globalink Investment Inc. extends deadline for initial business combination by obtaining first extension, approves charter and trust agreement amendments. The amendments to the charter and trust agreement will moderately influence Globalink's future business combination timeline and financial position.